Enhancement of CD47 blockade therapy by proteasome inhibitors
AssigneePF Argentum IP Holdings LLC
InventorsEmma Linderoth, Natasja Nielsen Viller, Robert Adam Uger, Penka Slavcheva Slavova-Petrova
Life of this patent
Estimating the term…
Abstract
CD47− disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
Claims29
A method for treating a subject with CD47+ disease cells comprising administering to the subject a combination of a CD47 blockade drug and a proteasome inhibitor, wherein the CD47 blockade drug comprises a CD47-binding form of human SIRPα, wherein the proteasome inhibitor is an epoxyketone.
A method for treating a subject with CD47+ disease cells comprising administering to the subject a combination of a CD47 blockade drug and a proteasome inhibitor, wherein the CD47 blockade drug comprises a CD47-binding form of human SIRPα, wherein the CD47 blockade drug is an Fc fusion protein comprising the V region of human SIRPα variant 2.
A method for treating a subject with CD47+ cancer cells, said subject receiving treatment with a proteasome inhibitor, the method comprising administering to the subject a CD47 blockade drug, wherein the CD47 blockade drug comprises a CD47-binding form of human SIRPα, and the amount of the CD47 blockade drug is effective to enhance the anti-cancer effect of the proteasome inhibitor wherein the CD47-binding form of human SIRPα comprises a polypeptide comprising the V region of human SIRPα variant 2, and wherein the CD47 blockade drug comprises the polypeptide comprising the V region of human SIRPα variant 2 fused to a polypeptide comprising an immunoglobulin constant region (Fc) wherein the CD47 blockade drug comprises the amino acid sequence of SEQ ID NO:
- 9 or SEQ ID NO:
- 10.
A combination comprising an amount of a CD47 blockade drug and an amount of a proteasome inhibitor, wherein the CD47 blockade drug comprises a CD47-binding form of human SIRPα, and wherein the amounts are such that the anti-cancer effects of one of the CD47 blockade drug and the proteasome inhibitor is effective to enhance the anti-cancer effect of the other wherein the CD47-binding form of human SIRPα comprises a polypeptide comprising the V region of human SIRPα variant 2, and wherein the CD47 blockade drug comprises the polypeptide comprising the V region of human SIRPα variant 2 fused to a polypeptide comprising an immunoglobulin constant region (Fc).
A method for treating a subject, said subject having CD47+ cancer cells and receiving treatment with a CD47 blockade drug, wherein the CD47 blockade drug comprises a CD47-binding form of human SIRPα, the method comprising administering to the subject a proteasome inhibitor in an amount effective to enhance the anti-cancer effect of the CD47 blockade drug, wherein the CD47-binding form of human SIRPα comprises a polypeptide comprising the V region of human SIRPα variant 2, and wherein the CD47 blockade drug comprises the polypeptide comprising the V region of human SIRPα variant 2 fused to a polypeptide comprising an immunoglobulin constant region (Fc).
Dependencies are inferred from the claim text.